We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.18%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.32B
AUM Growth
+$87.8M
Cap. Flow
+$6.46M
Cap. Flow %
0.49%
Top 10 Hldgs %
27.55%
Holding
138
New
17
Increased
50
Reduced
27
Closed
18

Top Buys

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$28.2M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$22.2M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$17.8M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$17.5M
5
AGN
Allergan plc
AGN
+$10.7M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$38M
2
STJ
St Jude Medical
STJ
+$33.4M
3
TMH
Team Health Holdings Inc
TMH
+$17M
4
ADPT
Adeptus Health Inc
ADPT
+$14.4M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 77%
2 Financials 3.37%
3 Industrials 0.48%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COO icon
76
Cooper Companies
COO
$14.5B
$5.91M 0.45%
176,000
-71,600
-29% -$2.56M
KYNB
77
Kyntra Bio
KYNB
$29.4M
$5.79M 0.44%
7,600
– –
CO
78
DELISTED
Global Cord Blood Corporation
CO
$5.61M 0.42%
880,000
– –
FPRX
79
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5.6M 0.42%
135,000
+15,000
+13% +$503K
FOLD
80
DELISTED
Amicus Therapeutics
FOLD
$5.5M 0.42%
566,500
+111,500
+25% +$1M
OTIC
81
DELISTED
Otonomy, Inc.
OTIC
$5.48M 0.42%
197,500
-123,300
-38% -$3.07M
ABBV icon
82
AbbVie
ABBV
$435B
$5.18M 0.39%
87,500
-658,923
-88% -$38M
CGEN icon
83
Compugen
CGEN
$228M
$5.14M 0.39%
805,000
+280,000
+53% +$1.84M
AGN.PRA
84
DELISTED
Allergan plc
AGN.PRA
$5.14M 0.39%
5,000
– –
NVTA
85
DELISTED
Invitae Corporation
NVTA
$5.11M 0.39%
622,900
+112,900
+22% +$889K
ASND icon
86
Ascendis Pharma A/S
ASND
$16.8B
$4.95M 0.37%
270,000
– –
KITE
87
DELISTED
Kite Pharma, Inc.
KITE
$4.93M 0.37%
80,000
-11,500
-13% -$809K
GI
88
DELISTED
EndoChoice Holdings, Inc.
GI
$4.93M 0.37%
590,000
+14,000
+2% +$135K
NVCR icon
89
NovoCure
NVCR
$1.91B
$4.79M 0.36%
+214,316
New +$5.12M
AIMT
90
DELISTED
Aimmune Therapeutics
AIMT
$4.79M 0.36%
259,646
+59,646
+30% +$1.1M
DYAX
91
DELISTED
DYAX CORPORATION
DYAX
$4.67M 0.35%
124,000
+9,500
+8% +$305K
CLVS
92
DELISTED
Clovis Oncology, Inc.
CLVS
$4.38M 0.33%
+125,000
New +$8.06M
PRGO icon
93
Perrigo
PRGO
$1.78B
$4.34M 0.33%
+30,000
New +$4.61M
CDTX
94
DELISTED
Cidara Therapeutics
CDTX
$4.29M 0.33%
12,500
-1,250
-9% -$375K
SRPT icon
95
Sarepta Therapeutics
SRPT
$1.77B
$4.15M 0.31%
+107,500
New +$3.49M
ATYR
96
aTyr Pharma
ATYR
$50.1M
$4.08M 0.31%
29,657
+1,872
+7% +$266K
SCYX icon
97
SCYNEXIS
SCYX
$52M
$3.94M 0.3%
7,938
+2,063
+35% +$1.09M
ALPN
98
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.79M 0.29%
122,250
– –
DVAX
99
DELISTED
Dynavax Technologies
DVAX
$3.62M 0.27%
150,000
– –
RIGL icon
100
Rigel Pharmaceuticals
RIGL
$750M
$3.33M 0.25%
+110,000
New +$3.34M
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Rock Springs Capital Management held 138 positions worth $1.32B, up 7.1% from $1.23B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q4 2015 filing shows 17 new, 50 increased, 27 reduced and 18 closed positions. Its largest new stake was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M. The largest sale was AbbVie, an estimated $38M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 76% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2015 buy was BAXALTA INC COM STK (DE): 810,000 shares worth $31.6M.
  • Rock Springs Capital Management added most to Allergan plc in Q4 2015, an estimated $10.7M increase.
  • Rock Springs Capital Management's biggest Q4 2015 reduction was AbbVie, cutting an estimated $38M.
  • Rock Springs Capital Management fully exited St Jude Medical in Q4 2015, selling an estimated $33.4M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.32B portfolio in Q4 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 18 in Q4 2015.
  • Rock Springs Capital Management's portfolio value rose 7.1% quarter-over-quarter to $1.32B.

Based on Rock Springs Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.